Licepler (Eplerenone)

Eplerenone selectively blocks aldosterone from binding to mineralocorticoid receptors in the distal nephron. This inhibition reduces sodium reabsorption and potassium excretion, leading to decreased fluid volume, lower blood pressure, and attenuation of aldosterone‑driven cardiac remodeling.

The appropriate dose of Licepler is determined by the prescribing clinician based on the individual’s medical condition, renal function, and potassium levels. Dosage adjustments are made according to therapeutic response and laboratory monitoring.

Eplerenone is classified as Pregnancy Category B, indicating no evidence of risk in animal studies but insufficient human data. It should be used during pregnancy only if clearly needed. Breastfeeding is not recommended unless the benefit outweighs potential risk to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Licepler (eplerenone) is a selective aldosterone receptor antagonist with a lower affinity for androgen and progesterone receptors compared with spironolactone, resulting in fewer hormonal side effects such as gynecomastia. Its efficacy in hypertension and heart‑failure management is comparable, while its safety profile may be more favorable for patients sensitive to endocrine effects.

Licepler tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children.

Licepler is taken orally, usually once daily, with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically advised.

The most serious risks include severe hyperkalemia, which can cause cardiac arrhythmias, and acute renal impairment. Patients should be monitored regularly for serum potassium and kidney function, and the drug should be discontinued if dangerous elevations occur.

Licepler is contraindicated in patients with known hypersensitivity to eplerenone, those with baseline hyperkalemia (serum K+ > 5.0 mmol/L), severe renal impairment (eGFR < 30 mL/min/1.73 m²), and in individuals with severe hepatic dysfunction. Caution is also advised for patients on concurrent potassium‑raising therapies.